Impact of vaccine delays at the 2, 4, 6 and 12?month visits on incomplete vaccination status by 24?months of age in Quebec, Canada

摘要

Timeliness in the administration of recommended vaccines is often evaluated using vaccine delays and provides more information regarding the susceptibility of children to vaccine-preventable diseases compared with vaccine coverage at a given age. The importance of on-time administration of vaccines scheduled at the first visit is well documented, but data are scarce about the impact of vaccine delays at other visits on vaccination status by 24?months of age. Using vaccine delays for the first three doses of DTaP-containing vaccines and for the first dose of measles-containing vaccines as markers of timeliness at the 2, 4, 6 and 12?month visits, we estimated the proportion of incomplete vaccination status by 24?months of age attributable to a vaccine delay at each of these visits. We used the data from six cross-sectional coverage surveys conducted in the Province of Quebec from 2006 to 2016 which included 7183 children randomly selected from the universal health insurance database. A vaccine dose was considered delayed if received 30?days or more after the recommended age. The impact of new vaccine delays at each visit on incomplete vaccination status by 24?months of age was estimated with the attributable risk in the population. The proportion of children with vaccine delay was 5.4% at 2?months, 13.3% at 4?months, 23.1% at 6?months and 23.6% at 12?months. Overall, 72.5% of all 2-year-old children with an incomplete status by 24?months were attributable with a vaccine delay, of which 16.1% were attributable with a first vaccine delay at 2?months, 10.6% at 4?months, 14.0% at 6?months and 31.8% at 12?months. While great emphasis has been put on vaccine delays at the first vaccination visit, the prevalence of vaccine delays was greater with later visits and most children with an incomplete vaccination status by 24?months had a vaccine delay occurring during these later visits. Interventions to improve timeliness should address vaccine delays at each visit and not only focus on the first visit.